Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BMS-212122
Cat. No.:
0225LY-1243
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BMS-212122 acts as a potent MTP inhibitor with hypolipidemic effects, significantly reducing lipid content and monocyte-derived cells in atherosclerotic plaques.
Synonym:
BMS212122; BMS 212122; 194213-64-4; 9H-Fluorene-9-carboxamide, 9-(4-(2,5-dimethyl-4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1H-benzimidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-; CHEMBL355007; 9-[4-[2,5-dimethyl-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)fluorene-9-carboxamide; 9-(4-(2,5-dimethyl-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)-1H-benzo[d]imidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide
CAS No.:
194213-64-4
Compound CID:
9853566
Formula:
C43H36F6N4O2
Formula Weight:
754.76
Specification
Relative Density:
1.31 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BMS-212122 can be used in metabolic studies to examine the potential of MTP inhibition in treating hyperlipidemia.
Library Information
Target:
MTP
Receptor:
MTTP
Pathways:
Metabolism
Plate Number:
AOCL-16
Plate Location:
h10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 66.25 mM
